Clinical trials launch to evaluate antimalarial, antidepressant drugs to treat COVID-19
The trial in hospitalized patients is evaluating the antimalarial drugs chloroquine and hydroxychloroquine. Infectious diseases specialists Rachel M. Presti, MD, PhD, an associate professor of medicine, and Jane O’Halloran, MD, PhD, an assistant professor of medicine, give COVID-19 patients one of the drugs — either in combination with the antibiotic azithromycin or by itself —to see whether it might speed recovery and prevent some of the worst problems associated with the viral infection.
In another study, researchers are repurposing a psychiatric medication to try to prevent the excessive inflammatory response to the virus that lands many in the hospital. Eric J. Lenze, MD, the Wallace and Lucille Renard Professor of Psychiatry, and infectious diseases specialist Caline Mattar, MD, an assistant professor of medicine, are testing the drug fluvoxamine. Normally used to treat psychiatric problems, the drug also inhibits a receptor linked to inflammation. The researchers are delivering the drug to COVID-19 patients at their homes. They then check in with the patients via computer and smartphone to monitor vital signs for several days while the patients take fluvoxamine. The goal is to prevent the excessive inflammation that lands many COVID-19 patients in intensive care units.
The podcast, “Show Me the Science,” is produced by the Office of Medical Public Affairs at Washington University School of Medicine in St. Louis.
Create your
podcast in
minutes
It is Free